COPDforum - COPD Presentation Builder

Slide #	Name	File	Type	Length (sec)
7001	Chapter 1 - Features of Systemic COPD	Chapter_1_Features_of_Systemic_COPD.wmv	wmv	1:09 sec
7002	Chapter 2 - Aetiology of Systemic COPD	Chapter_2_Aetiology_of_Systemic_COPD.wmv	wmv	1:04 sec
7003	Chapter 3 - The Need for Systemic Anti-Inflammatory Therapy	Chapter_3_The_Need_for_Systemic_Anti_Inflammatory_Therapy.wmv	wmv	0:50 sec
7004	Full Video - Systemic Features of COPD	Full_Video_Systemic_Features_of_COPD.wmv	wmv	2:37 sec

COPD Case Studies
- Case Study in COPD: Comorbidity in the Patient with COPD Differential Diagnosis and Treatment Selection
- Case Study in COPD: Distinguishing COPD from Adult Asthma
- Case Study: Biomass Fuel Exposure
- Case Study: COPD in a Patient with Difficulty in Stopping Smoking
Biomarkers
- Biomarkers in COPD
- Biomarkers
- Biomarker Definition: US Food and Drug Administration (FDA)
- Assessing Biomarkers
- Limitation of Biomarkers
- Biomarkers Associated With Increased Susceptibility for COPD
- Biomarkers Associated With COPD
- Stable COPD
- CRP
- CRP
- Serum CRP Levels Are Elevated in Stable COPD
- Serum CRP Levels Rise With COPD Severity
- Changes From Baseline in Serum CRP With Fluticasone and Fluticasone/Salmeterol
- Variable Results Relating Biomarkers to Prognosis: Serum CRP Is Associated With Mortality Risk
- Variable Results Relating Biomarkers to Prognosis: Serum CRP Is Not Associated With Mortality Risk
- Fibrinogen
- Serum Fibrinogen Is Elevated in Patients With COPD
- Serum Fibrinogen Levels Are Elevated Prior to Exacerbations
- Elevated Plasma Fibrinogen Is Associated With Increased Risk for Hospitalisation
- IL-6
- IL-6
- Serum IL-6 Is Elevated in Patients With COPD
- Elevation of Serum IL-6 in Patients With Exacerbations
- Surfactant Proteins
- Surfactant Protein D
- Actions of Surfactant Protein D
- Effects of Smoking on Surfactant Protein D
- Serum Surfactant Protein D Is Elevated in COPD Patients Versus Smokers and Nonsmokers
- Serum Surfactant Protein D Levels Are Negatively Correlated With FEV1
- Effect of ICS/LABA on Serum Surfactant Protein D in COPD
- Effects of Prednisolone on FEV1 and Serum Surfactant D Levels in COPD Patients
- Sputum Factant Protein A Is Elevated in COPD
- Clara Cell Protein
- Clara Cell Protein (CC16)
- Serum CC16 Levels Are Decreased in COPD
- Other Markers in Stable COPD
- Sputum Neutrophil Count Correlates With Declining Lung Function
- Serum TNF-a Is Elevated in COPD
- Sputum IL-8 Is Elevated in COPD
- Plasma IL-13 Level Is Negatively Correlated With FEV1
- Serum Interleukin-18 Is Elevated in Severe and Very Severe COPD
- Serum Interleukin-18 Is Negatively Correlated With FEV1
- Alveolar Macrophages in COPD
- IL-32 Is Elevated in Alveolar Macrophages From COPD Patients
- Blood Granzyme B Is Elevated in COPD
- Serum Elastase Is Negatively Correlated With FEV1
- Sputum Chaemokines: CXCR3 Is Elevated in COPD
- Chaemokines: Sputum CCL5 (Rantes) Is Elevated in COPD
- Sputum MMP-12 Is Elevated in Patients With COPD
- Serum Matrix Metalloproteinase-9 Is Elevated in COPD
- Plasma Brain Natriuretic Peptide Is Elevated in COPD
- Sputum Vascular Endothelial Growth Factor IsRelated to Pulmonary Haemodynamicsin COPD Patients
- YKL-40 Is Elevated in the Lungs andPeripheral Blood of Smokers With COPD
- Association of Serum Biomarkers With FEV1
- Relationship Between Inflammatory Markers and Symptom Severity
- ATP in BALF Is Increased in Smokers
- Sputum Lipocalcin-1 and Apolipoprotein A1 Are Elevated in Patients With COPD
- Plasma Markers Related to Rate of Pulmonary Decline in COPD
- Plasma Markers Related to Rate of Pulmonary Decline in COPD (contd)
- Plasma IL-4 Is Elevated in COPD Patients With A Rapid Decline in Pulmonary Function
- Differentiation of COPD from Asthma
- Biomarkers in Induced Sputum of PatientsWith COPD and Chronic Asthma
- Risk for Hospitalisation and MortalityIncreases With Serum CRP Level
- Fibronectin: CRP Ratio Predicts Cardiovascular Mortality
- Risk for Exacerbations
- Plasma Brain Natriuretic Peptide and Exacerbation Risk
- Association of Serum Biomarkers With Exacerbation Frequency
- During Exacerbations
- Sputum and Serum Markers Associated With Exacerbations
- Biomarkers Elevated During Exacerbations
- Plasma Inflammatory Markers Elevated During Exacerbations
- Serum CRP and Amyloid A Are Transiently Elevated During Exacerbations
- Outcomes Post-exacerbation
- Plasma B-Type Natriuretic Peptide Predicts Admission to the ICU in COPD Patients With Exacerbations
- Plasma Copeptin Levels Are Associated With Increased Mortality and Morbidity in COPD Patients With Exacerbations
- Troponin Levels Predict Long-term Mortality in COPD Patients With Exacerbations
- Limitations of Biomarkers
- Variability
- Wthin- and Between-Day Variability for LTB4 and 8-Isoprostane
- Biomarkers: Current Use and Utility
- ATS/ERS Conclusions Regarding Biomarkers
- Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE)
- Biomarkers That Distinguish COPD Patients From Smokers
- Biomarkers That Distinguish COPD Patients From Smokers
- Biomarkers That Distinguish COPD Patients From Smokers (contd)
Exacerbations
- Exacerbations
- Contents
- Definition and Symptoms
- Definition of COPD Exacerbations
- Exacerbations May Be Defined by Symptoms or Healthcare Utilisation
- Symptoms and Diagnosis of COPD Exacerbations
- Differential Diagnosis of COPD Exacerbations
- Burden of Unreported Exacerbations
- Epidemiology and Impact
- Factors Associated With Increased Risk for Exacerbations
- Elevated Exacerbation Risk Associated With Cough and Sputum Production
- Early Chronic Bronchitis Symptoms Are Predictive of Mortality
- Risk Factors for Frequent Exacerbations
- Effects of Frequent Exacerbation on Pulmonary Function
- Frequent Exacerbations Are Associated With Reduced Quality of Life
- Chronic Phlegm Production Increases Risk for Exacerbations in Severe Early-Onset COPD
- Epidemiology of Exacerbations: Frequency Increases With Declining FEV1
- The Body Mass Index, Obstruction, Dyspnoea, Exercise Capacity (BODE) Index Predicts Exacerbation Frequency
- Impact of Exacerbations in COPD
- Pulmonary Function May Recover Slowly After an Exacerbation
- More Rapid Decline in FEV1 With Higher Exacerbation Frequency
- Mortality Following Emergency Department Visit for COPD Exacerbation
- Exacerbation Frequency and Severity Both Increase Mortality Risk
- ECLIPSE: Factors Associated With Increased Exacerbation Frequency
- Patients' Perceptions of Exacerbations
- Effect of Exacerbations on Time Spent Outdoors
- Cost of Treatment for an Acute Exacerbation of COPD
- Exacerbations Are the Main Cost Driver in COPD
- Patterns of Recovery From Exacerbations
- Pathophysiology and Aetiology
- Pulmonary and Systemic Inflammation in Exacerbations
- Potential Causes of Exacerbations
- Pathogens
- Relationship Between FEV1 and Aetiology of Exacerbations
- Incidence of Virus Detection With PCR in Adult Populations
- High Presence of RSV Is Associated With More Rapid Decline in FEV1
- Aetiology of Exacerbations for Different COPD Stages
- Bacterial Load and Inflammation in Stable COPD
- Characterisation of Exacerbations
- Bacteria in Exacerbations Associated With Increased Inflammation - Purulent Versus Mucoid Sputum
- Recovery From Exacerbations: Viral Versus Non-viral
- Combined Viral and Bacterial Infection: Increased Impact on Pulmonary Function and Symptom Severity
- Inflammation Before and During Exacerbations
- Serum Inflammatory Mediators Elevated in Acute Exacerbations
- Inflammation at Exacerbations With Purulent Versus Mucoid Sputum
- CRP Elevations During Exacerbations in Patients With Mucoid and Purulent Sputum
- Inflammatory Markers Are Elevated Prior to Exacerbations
- Bronchial Neutrophils Are Increased During Exacerbations
- Neutrophils Are Increased in Exacerbations Regardless of Aetiology
- Bronchial Eosinophils Are Increased During Exacerbations
- Elevation of Serum Markers for Systemic Inflammation in Exacerbations
- Increased Inflammation During Exacerbations
- Plasma Inflammatory Biomarkers Elevated During Exacerbations
- MMP-9 Is Elevated During Exacerbations
- Pulmonary Inflammation Is Correlated With Decreased Pulmonary Function in Acute Exacerbations
- Systemic Inflammation Is Correlated With Decreased Pulmonary Function in Acute Exacerbations
- Preventing Exacerbations
- Influenza Vaccination: Risk for Any Exacerbation
- Pneumococcal Vaccination
- Salmeterol and Ipratropium Decrease Risk for Exacerbations
- Tiotropium Decreases Frequency of Exacerbations
- ICS Decreases Exacerbation Rate
- TORCH: Lower Exacerbation Rate With LABA Plus ICS
- UPLIFT Study - Effects on Exacerbations
- Roflumilast Significantly Reduced Exacerbations When Added to LABA
- Antibiotic Administration for Prophylaxis Against Exacerbations
- Indacaterol: Effects on Exacerbation Frequency
- Effects of Pulmonary Rehabilitation after Hospital Admission for an Exacerbation
- Pulmonary Rehabilitation
- Treating Exacerbations
- Use of Short-acting Bronchodilators in the Treatment of Exacerbations
- Use of Supplemental Oxygen in the Treatment of Exacerbations
- Indications for Considerations of Hospital Management of Exacerbations
- Indications for Possible Intensive Care Unit Admission for Exacerbations
- Meta-analysis of Efficacy: Systemic Corticosteroids and Risk of Treatment Failure
- Oral Corticosteroids for Treatment of Exacerbations
- Meta-analysis of Efficacy: Antibiotic Therapy and Risk of Treatment Failure
- Outcomes With Antibiotic Therapy in Patients Hospitalised With Exacerbations: Retrospective Cohort Study
- Antibiotic Treatment Decreases Mortality in COPD Patients Mechanically Ventilated for Exacerbation
- Meta-analysis of Efficacy: Antibiotic Therapy and Risk for Treatment Failure
- Meta-analysis of Efficacy: Antibiotic Therapy and Risk of Mortality
- Noninvasive Mechanical Ventilation (NIV)
- Meta-analysis of Efficacy: NIV
- Meta-analysis of Efficacy: NIV
- Oral Corticosteroids: Effect on FEV1 in Patients With Exacerbations
- Indications for Invasive Mechanical Ventilation
Patterns of Inflammation
- COPD: Patterns of Inflammation
- Contents
- Definition and Characterisation of COPD
- GOLD Definition of COPD
- COPD Is a Disease Characterised by Inflammation
- Genetic Factors in COPD
- Genetic Factors in COPD
- Additional Genetic Polymorphisms of Interest in COPD
- Inflammatory Cells in Stable COPD
- Neutrophils in COPD
- Sputum Neutrophil Count Correlates With Declining Lung Function
- Neutrophils Infiltrating Bronchial Glands in COPD
- Reduction in Neutrophil Apoptosis in COPD
- Alveolar Macrophages in COPD
- Inflammatory Mediators in Stable COPD
- CD8+ Cells in COPD
- The Greater the CD8+ Infiltration, the Greater the Airway Obstruction
- Increased CD8+ Cell Numbers in the Submucosa of Large and Small Airways, Vessels, and Alveolar Wall of Smokers Who Develop COPD
- Emphysema Is Associated With Inflammatory Cells in the Alveoli
- Numbers of Inflammatory Cells and Mediators Increase as Disease Progresses
- Inflammatory Mediators in COPD - Summary
- Examples of Chemotactic Factors in COPD
- TNF-a Has Pro-inflammatory Actions in COPD
- Levels of TNF-a in Exhaled Breath Condensate in Stable COPD and Exacerbations
- COPD Inflammatory Mediators: TGF-ß1
- Increased TGF-ß1 in COPD Small Airway Epithelium
- IL-6 Concentrations in Exhaled Breath Condensates
- Increased Bronchiolar Expressionof the T-Cell Chemokine Receptor CXCR3
- Elastins in the Development of Emphysema
- Actions of Proteinases in COPD
- Elevation of Matrix Metalloproteinase in COPD
- MMP-9 Is Elevated in Patients With COPD
- Cathepsins Are Elevated in Smokers
- Modulation of Inflammation by Histone Deacetylase (HDAC)
- Decreased HDAC Expression May Promote Inflammation and Decrease Response to ICS in COPD
- Pulmonary HDAC Levels Decrease With COPD Severity
- Oxidative Stress
- Airway Epithelium in COPD: Reactive Oxygen Species and Polymorphonuclear Cells
- Tissue Destruction and Remodeling
- Histopathological Features of COPD
- Inflammation Leads to Small Airway Narrowing
- Inflammation and Airway Destruction
- Mucous Glands Are Enlarged in COPD
- Mucous Plugging Obstructs Small Airways in COPD
- Volume of Airway Wall Tissue Correlates Significantly With Disease Progression
- Apoptotic Pathways in COPD
- Interaction of Apoptosis and Inflammatory Pathways in COPD
- Multiple Pathways Lead to Emphysema in a Murine Model
- Macroscopic Emphysema
- Alveolar Septal Cell Apoptosis and Emphysema
- The Greater the Airway Inflammation, the Greater the Destruction of Alveolar Attachments
- Angiogenesis in COPD
- Angiogenic and Angiostatic Factors in COPD
- VEGF in COPD
- VEGF Levels in Stable COPD
- Serum VEGF Is Elevated in COPD Exacerbations
- Inflammation in Acute Exacerbations
- Exacerbations of Chronic Bronchitis and Inflammatory Cell Types
- Increase in Neutrophils During COPD Exacerbations
- Exhaled 8-Isoprostane in Exacerbations
- Increased Neutrophils During Exacerbations of Chronic Bronchitis
- Increased Eosinophils During Exacerbations of Chronic Bronchitis
- Elevation of Serum Markers for Systemic Inflammation in Acute Exacerbations
- MMP-9 Is Elevated in Acute Exacerbations
- Clinical Consequences of Inflammation
- Progression From Molecular to Clinical Events in COPD Inflammation
- Clinical Impact of Inflammation in COPD
- Inflammation: Clinical Consequences
COPD Overview
- COPD Diagnosis, Staging, and Treatment: an Overview
- COPD Overview: Contents
- Definition of COPD
- The Downward Spiral in COPD
- Continuing Burden of COPD
- International Variation in COPD Prevalence
- At Risk for COPD
- Risk Factors for COPD
- Cumulative Exposure to Noxious Particles Is the Key Risk Factor for COPD
- Who Should Be Screened for COPD?
- Underdiagnosis of COPD in the United States
- Underdiagnosis of COPD in China
- COPD Misdiagnosis Is Common in Women
- GOLD Goals for COPD Treatment
- Diagnosis of COPD
- Measures of Pulmonary Function Commonly Used in COPD
- Spirometry for COPD Diagnosis and Classification of Severity
- Reversibility of Bronchodilator Response
- Spirometry
- Why Do We Need Spirometry?
- Diagnosis of COPD
- Partial Reversibility Is Common in COPD
- B-agonist Reversibility and Response to ICS/LABA Combination Treatment
- Differential Diagnosis: COPD and Asthma
- Inflammation in Asthma and COPD
- COPD and Comorbidities
- Reduce Risk Factors
- Reduce Risk Factors: Smoking Cessation
- Brief Strategies to Help the Patient Willing to Quit Smoking
- Smoking Cessation Requires Multiple Attempts
- COPD Risk and Smoking Cessation
- Benefit of Smoking Cessation: Lung Health Study 11-year Results
- Reduce Risk Factors: Indoor/Outdoor Air Pollution
- Stages of COPD: Treatment
- Benefits of Short-acting Bronchodilator Treatment in COPD
- Effects of Long-acting Bronchodilators on Lung Function
- Combination Therapy With Long-acting Bronchodilators Improves Lung Function
- TORCH: Effects of LABA Plus ICS on Mortality
- TORCH: Improvement in FEV1 With LABA Plus ICS
- UPLIFT: Improvement of Lung Function Over 4-Years With Tiotropium
- UPLIFT Study - Effects on Health Status
- Definition of COPD Exacerbations
- Impact of Exacerbations in COPD
- More Rapid Decline in FEV1 With Higher Exacerbation Frequency
- Management of Exacerbations
- TORCH: Lower Exacerbation Rate With LABA Plus ICS
Pharmacotherapy
- Management of COPD: Current Pharmacotherapy
- Contents
- GOLD Goals for COPD Treatment
- Pharmacological Treatments
- Mild COPD
- Short-acting Bronchodilators: Onset and Duration of Action
- Potential Side Effects of COPD Therapy: ß2-Agonists
- Potential Side Effects of COPD Therapy: Anticholinergic Agents
- Long-acting Bronchodilators in Moderate COPD
- Effects of Long-acting Bronchodilators on Lung Function
- Tiotropium Improves Exercise Tolerance
- UPLIFT: Improvement of Lung Function Over 4 Years With Tiotropium
- UPLIFT: FEV1 Results for Patients With Moderate COPD
- UPLIFT: Smoking Status and FEV1
- UPLIFT Study - Effects of Exacerbations
- UPLIFT: 4-year Evaluation of Tiotropium - Mortality
- UPLIFT: Results for Specific Patient Subgroups
- Tiotropium and Risk for Cardiovascular Events
- Indacaterol versus Salmeterol: Improvementin Trough FEV1 over 26 Weeks
- Bronchodilator Effects of Indacaterol and Formoterol in Patients With COPD
- Effects of Indacaterol, Tiotropium, and Placebo on FEV1
- Effects of Indacaterol and Formoterol on FEV1
- Long-acting Bronchodilators: Effects of Tiotropium, Formoterol, and Concomitant Therapy on FEV1
- Long-acting Bronchodilators: Effects of Adding Nebulised Formoterol to Tiotropium
- Effects of Long-acting Bronchodilators on Exacerbations
- INSPIRE: Effects of COPD Treatment on Mortality
- Severe-Very Severe COPD Pharmacotherapy
- Impact of Exacerbations in COPD
- Pulmonary Function May Recover Slowly After an Exacerbation
- Exacerbation Frequency and Severity Both Increase Mortality Risk
- ECLIPSE: Risk for Exacerbations
- Cough and Sputum Production Indicate an Increased Risk of Exacerbations
- Burden of Exacerbation
- Addition of Inhaled Corticosteroids to Bronchodilators
- Inhaled Corticosteroids
- Anti-inflammatory Effects of Salmeterol/Fluticasone Propionate in COPD
- Effect of Salmeterol/Fluticasone propionate on Airway Inflammation in COPD
- Anti-inflammatory Effects of Tiotropium, Salmeterol, and Fluticasone
- Correlations Between Effects of LABA Plus ICS on Inflammatory Cells and Pulmonary Function
- Efficacy of ICS in COPD
- Efficacy of ICS in Mild COPD Patients Who Continue to Smoke: EUROSCOP
- Effect of ICS Treatment on FEV1 Decline: Meta-analysis
- Effects of ICS on Pulmonary Function
- Effects of ICS on Symptoms and Quality of Life
- ICS Treatment and Cardiovascular Events in Patients With Mild COPD
- Effects of ICS on Vascular Remodeling and Associated Factors
- ICS Decreases Exacerbation Rate**
- TORCH: Lower Exacerbation Rate With LABA Plus ICS
- TORCH: Effects of Treatment on Exacerbations - Relation With Baseline FEV1
- Tiotropium Plus Budesonide/Formoterol: Effect Exacerbations and Hospitalisation/ER Treatment
- Effects of LABA Plus ICS in Different COPD Subtypes
- TORCH: Rate of Decline in Post-bronchodilator FEV1 With LABA Plus ICS
- TORCH: Mortality
- Tiotropium Plus Formoterol versus Fluticasone Plus Salmeterol: Effects on FEV1
- Tiotropium Plus Budesonide/Formoterol: Effect on FEV1
- Tiotropium Plus Budesonide/Formoterol: Effect on COPD Symptoms
- Tiotropium Plus Budesonide/Formoterol: Effects on Symptoms and Capacity of Daily Living
- The OPTIMAL Study: Effects of Treatment on FEV1
- The OPTIMAL Study: Effects on Treatment on Quality of Life
- The OPTIMAL Study: Effects on Exacerbations
- The OPTIMAL Study: All-cause Mortality
- Potential Side Effects of COPD Therapy: ICS
- Use of ICS and Risk for Pneumonia
- Risk for Pneumonia in TORCH
- Treatment With Budesonide Does Not Increase Pneumonia Risk
- Concern Regarding Pneumonia in Patients Treated With ICS
- Risk for Tuberculosis With ICS
- TORCH: Adverse Events
- Change in Bone Mineral Density (BMD) With COPD Treatment: Results from TORCH
- Risk for Cardiovascular Events With COPD Treatment: Results from TORCH
- Addition of PDE4 Inhibitors to Bronchodilators
- PDE4 Plays an Important Role in Inflammation
- PDE4 Inhibitors in COPD
- Roflumilast Reduced Levels of Inflammatory Markers in Sputum Samples
- Roflumilast Significantly Reduced Exacerbations When Added to LABA
- Roflumilast Reduced Exacerbation Rate When Added to ICS
- Roflumilast Reduced Exacerbations in Patients With COPD Associated With Chronic Bronchitis
- Effects on Prebronchodilator FEV1 After Treatment With Roflumilast 500 µg or Placebo
- Roflumilast Improved Lung Function When Added to First-line Maintenance Treatment
- PDE4 Inhibitors Included as a New Class of Treatment in 2010 GOLD Guidelines
- Roflumilast Well-tolerated by 12,000+ Patients in Clinical Studies
- Roflumilast Overview
- Vaccination
- Influenza Vaccination: Risk for Any Exacerbation
- Pneumococcal Vaccination
Systemic Inflammation and Comorbidities in COPD
- Systemic Inflammation and Comorbidities in COPD
- Systemic Inflammation and Comorbidities in COPD
- Systemic Inflammation
- Systemic Inflammation in COPD
- Systemic Inflammation in COPD: C-reactive Protein Is Elevated
- CRP Is Elevated in Patients With COPD versus Smokers and Nonsmokers
- Systemic Inflammation in COPD: TNF-a Is Elevated
- Systemic Inflammation in COPD: Fibrinogen Is Elevated
- Systemic Inflammation in COPD: Elevated Leucocytes
- Systemic Inflammation in COPD: Elevated VEGF
- Systemic Inflammation Rises With COPD Severity
- Comorbidities in COPD
- Higher Rates of Hospitalisation Due to Comorbidities in COPD
- Death Due to Comorbidities Is More Common in COPD
- Hospitalisations in Patients With COPD
- Systemic Inflammation in COPD: Potential Clinical Consequences
- Skeletal Muscle Dysfunction
- Skeletal Muscle Apoptosis in COPD
- Fat-free Mass Is Reduced in COPD
- COPD and Cachexia
- Systemic Inflammation and Muscle Wasting in COPD: Suggested Model
- Relationship Between Skeletal Muscle Mass and Inflammatory Markers in COPD
- Cardiovascular Disease
- Inflammation in Cardiovascular Disease
- COPD Inflammation Can Contribute to Cardiovascular Disease
- Risk for Cardiovascular Disease in COPD Patients and Matched Controls
- Risk for Ischaemic Heart Disease as a Function of Pulmonary Function
- Risk for Stroke as a Function of Pulmonary Function
- Respiratory Symptoms and Cardiovascular Mortality
- Arterial Stiffness in COPD Patients
- Arterial Stiffness Is Independently Associated With Emphysema Severity in Patients With COPD
- Osteoporosis
- Osteoporosis
- Airflow Obstruction and Osteoporosis in COPD
- Risk Factors for Osteoporosis in COPD
- Inflammatory Mediators in Osteoporosis
- Bone Turnover and Osteoporosis are Correlated With Inflammation
- COPD, ICS, and Osteoporotic Fracture
- Inhaled Versus Oral Corticosteroid Use and Fracture Risk in COPD
- Anaemia of Chronic Disease
- Inflammatory Processes and Anaemia
- Anaemia Increases Mortality Risk in Patients With COPD
- Anaemia and Mortality in COPD
- Metabolic Abnormalities in COPD
- Tumor Necrosis Factor-a and Diabetes
- Reduced Pulmonary Function Associated With Diabetes Mellitus
- Insulin Resistance Is Elevated in COPD Patients and Correlated With Inflammatory Markers
- Prevalence of Diabetes Higher in Patients With COPD
- Prevalence of Metabolic Syndrome Higher in COPD
- Depression
- Risk of Depression in Patients With COPD
- Variables Associated With Depression and Anxiety in Patients With COPD
- Gastrointestinal Disease
- Helicobacter pylori and Inflammatory Mediators in Gastric Disease
- Increased Prevalence of Esophagitis, Gastritis, or Gastric Ulcers in Patients With COPD
- Increased Risk for COPD Mortality in Patients With Chrohn's Disease
- Effects of COPD Treatment on Systemic Comorbidities
- Effects of Tiotropium on Inflammatory Markers in COPD Patients
- Changes From Baseline in CRP and IL-6 With Fluticasone and Fluticasone/Salmeterol
- Systemic Comorbiditites in COPD
- Systemic Comorbiditites in COPD
- Assessing Comorbidities in COPD
The Global Burden of Chronic Obstructive Pulmonary Disease
- The Global Burden of Chronic Obstructive Pulmonary Disease
- Continuing Burden of COPD
- COPD: Global Burden
- Limitations in Assessing the Global Burden of COPD
- Worldwide Prevalence of COPD
- International Variation in COPD Prevalence
- COPD in the European Union
- Prevalence of COPD in South America: Platino Study
- COPD Severity in South America: Platino Study*
- Death and Disability Due to Respiratory Disease Worldwide
- COPD Is an Increasingly Common Cause of Death Worldwide
- COPD Mortality Is Increasing Versus Other Diseases (United States Data)
- Mortality Risk Is High in COPD Patients: UPLIFT
- Underdiagnosis of COPD in the United States
- Underdiagnosis of COPD in China
- Passive Smoke Exposure Increases COPD Risk in China
- Burden of Disease Attributable to Tobacco and Indoor Smoke From Solid Fuel
- COPD Misdiagnosis Is Common in Women
- Evidence for COPD Undertreatment
- COPD Fast Facts: Impact of Disease
- COPD Burdens Healthcare Resources
- Hospitalisation and ER Visits
- Hospitalisation for COPD in the United States
- Risk for COPD Hospitalisation Increases With Age
- Respiratory Symptoms and Smoking Are Associated With Higher Hospitalisation Rates
- Long-Term Outcomes in Mild/Moderate COPD: Respiratory Symptoms and Smoking Are Associated With Higher FEV1 Decline
- US Direct and Indirect Costs of COPD
- Economic Impact of COPD
- Activity Is Decreased in COPD Patients
- Limitations in Activities for All COPD Patients
- Quality of Life Declines With COPD Severity
- Action Plan for the Global Strategy for the Prevention and Control of Non-communicable Diseases
- Action Plan for the Global Strategy for the Prevention and Control of Non-communicable Diseases
- GOLD Goals for COPD Treatment
- Anti-Smoking Legislation Is Associated With Decreased COPD Mortality
- Who Should Be Screened for COPD?
Images
- CD8 Cell
- CD4 Cell
- Neutrophil
- Macrophage
- Epithelial Layer
- cAMP in PDE4
- cAMP
Videos
- Chapter 1 - Features of Systemic COPD
- Chapter 2 - Aetiology of Systemic COPD
- Chapter 3 - The Need for Systemic Anti-Inflammatory Therapy
- Full Video - Systemic Features of COPD
Hot Topics
- Hot Topic #1: Rennard et al

View All

Access

COPD Presentation Builder

Be The First To Know!